Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
One by one, each sector appears to be topping or reversing.
This time, it’s biotech.
Analysis (and action) over the past year has been on again, off again and now, appears to be back on again.
However, this time we have (as we’ll see below) a near perfect Fibonacci correlation.
Biotech Sector Index SPBIO, Daily
First, the big picture.
The corrective retrace that started way back in late October, of last year.
Next, we’ll get in closer to show the exactness of the Fibonacci levels.
It hardly ever works out this perfectly, but there it is.
Change Horses?
It’s no secret, the focus of trading action on this site since mid-October, has been to short semiconductors, potentially the largest bubble (A.I.) in world history (not advice, not a recommendation).
However, biotech may get its comeuppance as well with information like this, this and this hitting the mainstream.
The decision to take action or not, remains open (not advice, not a recommendation).
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Moderna, MRNA, is down -88%, from its all-time highs.
Having worked the markets for nearly forty-years, it (typically) goes as follows …
When a stock declines 80% or more, in short order (12-36 months or so), those with absolutely no analysis skills or discipline, who bought-in because everyone else is doing it (making a supposed fortune), have now lost their shirts.
So, they do what they know best, blame somebody else. Let the lawsuits begin.
The whole thing is so much like High School.
Class action is nothing new. What is new this time around, or what could be new, is the ‘discovery’ process.
One has to wonder if (or when) the lawyers are going to come across this piece of ‘discovery’.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
For a clue to the (potential) answer, we can look at what’s happening to Pfizer, link here and here.
However, let’s not get ourselves wrapped around the axle on events, forecast years ago.
Rather, let’s go straight to the truth, the price action and see what it’s telling us.
Moderna MRNA, Weekly
The entire move from low to highs is shown. Included on the chart, are two Fibonacci indicators.
One is the standard ‘retrace’ indicator; the other, is a ‘projection’ indicator.
The ‘projection’ is based off the ‘a-b-c’ move from the lows of November 2nd, 2023, to the highs on May 24, 2024.
The retrace and projections are hard to see, so the ‘Detail‘, arrow is where we’re headed next on the daily.
Moderna MRNA, Daily
If there ever was a chart to once-and-for-all, refute, dismiss, trash, the whole ‘Fundamentals’ argument, that earnings, interest rates or some other ‘Voodoo economics’, moves prices, this is it:
MRNA, price action hit the 23.6% retrace level (exactly) for two days before moving on to hit the 161.8%, projection (exactly) before reversing.
Note the ‘100%‘ level as well; price action confirmed this area (exactly) three times! Once on the way up and two times on the way down (third time, not shown).
A century ago, Livermore said, ‘It’s all about the numbers’.
Strategy, First
Just as Livermore was primary a strategist, so is this site’s method of analyzing the markets, i.e., Strategy, Tactics, Focus, in that order (not advice, not a recommendation).
The news has been replete with reports like this one and this one.
Another panic ahead?
Sounds like it but at least in the case of Moderna, the chart itself says (effectively):
‘There’s no money in it’.
That means, another wave like we saw several years ago, is not the most likely future event (not advice, not a recommendation).
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
With today’s heavy downward action, as we head into the close, any number of scenarios could play out.
Work has already been done on INTC, KMX, MRNA, Biotech Leveraged Inverse LABD, and others.
With such a decisive push lower, there could be some kind of short covering late in the session.
For example, as of this post 2:15 p.m. EST, KMX (detailed below) appears to be coming off the day’s lows.
CarMax Weakness
The daily chart has KMX, right a the bottom of a trading channel.
Price action may continue to rebound from this area heading into the close or not.
If there’s a rebound, naturally Put options will begin to decay in value … a desired outcome if one is looking to enter short (at the cheapest price possible).
The bottom of the channel line could be all there is for this week or we could be heading to much lower levels.
It’s up to the trader/speculator to decide (not advice, not a recommendation)
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
With that understood, we’ll present three potential scenarios for Moderna (MRNA) price action for the upcoming days, or week(s).
When we last left our chief cook and spike-protein injector, price action was in a downtrend but also in Wyckoff spring position; indicating at least a chance for upside.
As with the CarMax (KMX) analysis, still playing out with Scenario No. 2, and/or No. 3, at this link as the forecasted price action, we’ll show potential Scenario No. 1 – No. 3, for MRNA, below.
Moderna MRNA, Daily, Forecasted Action
Scenario No. 1
Upside wedge breakout
Scenario No. 2
Downside wedge breakout with no test
And now, the most probable, ‘If there’s a downside breakout.
From a short-dated options standpoint, Scenario No. 3, is the most desirable (not advice, not a recommendation).
If there’s a downside breakout with no test, there’s always the possibility at some point, there will be a test, which in turn completely wipes out any potential gain in the (put) trade; time would run out and the option expires.
Re-Visiting, Elder
Recall, in the example that Dr. Elder gave, he bought OEX Put Options at 3/8-ths, back in the day when the markets traded in fractions.
Three-eighths is 0.375, which gives a target value on which option to select (not advice, not a recommendation).
To get to that small of a fraction, the option’s either way out of the money, short on time, or both.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
With a potential right-side trend (and channel) contact confirmed; shown below at – 86% annualized, odds are now favorable for a Put strategy.
In addition to the technical factors discussed, listed at the bottom of this post are no fewer than 22-links to the current fundamental state of biotech and their ‘handiwork’.
The weekly chart of MRNA, has a Wyckoff Up-Thrust and a test, confirmed by the downside pivot.
Moderna MRNA, Weekly
Notice the reversal action took place at a very weak Fibonacci 23.6% retrace.
The two blue lines on the daily chart (below) are exactly parallel.
The grey lines are parallel to the blue lines and intended to show MRNA, exhibits a repeating (downtrend) pattern.
Moderna MRNA, Daily
The expanded version on the daily has support being penetrated (horizontal blue line) and then ‘spring’ action last Friday as a result.
Of course, it’s ‘what happens next’, that’s the question.
In a prefect scenario, price action would thrust lower for a day or several days and then come back up to test the underside of resistance.
Elder Option Strategy
This strategy is taken from Elder’s book ‘Come Into My Trading Room’, and seeks to use as short-dated options as possible.
Doing so, requires the discipline to wait sufficient amount of time for price action to get into position and for option time value to bleed-off.
Potential Upside
Since we’re already in spring position and price action moved off the lows on Friday, MRNA could continue the upside right back to, or past the downtrend line.
However, with massive (undeniable) fundamentals building buy the day, and MRNA being mentioned specifically in at least one link below, probabilities favor the downside.
Supporting Links For The Bearish Stance
Florida Surgeon General Warns Life-Threatening VAERS Reports Up 4,400 Percent Since COVID-19 Vaccine Rollout
US Says Government, Not Moderna, Should Face COVID-19 Vaccine Lawsuit
New Medical Codes For COVID Vaccination Status Raise Concerns Among Experts
Watch: Rand Paul Grills School Of Nursing Head On Student COVID Vaccine Mandate
US Navy Lifts COVID Vaccine Mandate For Sailor Deployment
Mainstream Media Continues To Push False ‘COVID Heart’ Narrative To Explain Excess Deaths
NFL Players’ Association Urged To Screen for Heart Issues Over Vaccine Side Effects
WHO Suddenly Shelves Plans For Second Phase Investigation Into Origins Of COVID-19: Report
Watch: CDC Director Suggests It Will Never Change Child-Masking Policy
Rand Paul Introduces Bill To Halt Funding For Hospitals Denying Care To The Unvaxxed
Welfare State Weakens… 30 Million Americans Are About To Lose ‘COVID’ Food Stamp Handouts
IMF Says World Needs To Prepare For The “Unthinkable” After COVID, War In Ukraine
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
The last update about our chief cook and bottle washer of gene ‘modification’ had this to say about price action.
“We’re about forty minutes into the session; Moderna (MRNA) has just confirmed the up-thrust reversal discussed in the last update“.
From that point Moderna (MRNA) declined for seven weeks for a total of around – 31.5%.
However, that’s not the most important part.
In that update, a trading channel was shown which at the time, was declining at – 93.7%, on an annualized basis.
Well, the channel is back.
Only this time, probabilities and price action have come together to set up for a potential sustained decline.
Moderna MRNA, Weekly
Above, we have a Wyckoff ‘Up-Thrust’ and a test that has since turned lower.
Next, we have a series of repeating trend or channel lines.
Additional data has modified the downward slope to be declining at approximately – 90%, annualized.
From a fundamental standpoint, the data set is enormous on the events of the past three years.
At some point that data could provide a huge tailwind for downside action.
For now however, let’s stick with what price action is telling us and go to the Summary & Strategy
Summary & Strategy
The past week has identified two areas of position or trade execution and two areas for possible short-term options execution (not advice, not a recommendation):
Position or Trade: Real Estate IYR, and Biotech SPBIO
Options: Carmax KMX, and Moderna MRNA
As a reminder, most if not all trade analysis is for the short side (not advice, not a recommendation).
Final Thoughts
Since we have possibly the largest bull trap in market history with huge numbers of VIX Call options, the following week may be subdued by going modestly up, sideways or down, slowly.
With that said, options positioning (if any) could be slated for the week of 2/17/23.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
The Danger Point® 